治疗是否增强了我们对中轴型脊柱关节炎的认识？
Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?
机构信息
The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine (LIRMM), NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK.
The University of Leeds, Leeds Institute of Cardiovascular and Metabolic Medicine, the LIGHT building, Clarendon Way, Leeds, UK.
出版信息
Curr Rheumatol Rep. 2023 Mar;25(3):56-67. doi: 10.1007/s11926-023-01097-7.
PURPOSE OF REVIEW
An overview of how the treatment landscape of axial spondyloarthritis (axSpA) has shaped our understanding of the disease.
RECENT FINDINGS
Prior to the millennium, non-steroidal anti-inflammatory drugs (NSAIDs) were the only treatment for axSpA, yet only 30% of patients responded and many developed side effects. In 2003, the first biological disease-modifying drug (bDMARD) was licensed for axSpA which substantially improved outcomes in comparison to NSAIDs. In 2022, there are now several bDMARDs for axSpA; however, they too are not universally efficacious in treating axial inflammation and may have deleterious effects on extramusculoskeletal manifestations. Nevertheless, successful or not, each bDMARD gives invaluable insight into axSpA immunobiology. This review discusses how much we have learned from the use of bDMARDs in axSpA, how this has redefined our understanding of the disease, and how we might use this knowledge to develop new and better treatments for axSpA in the future.
综述目的
概述轴性脊柱关节炎（axSpA）的治疗现状如何改变我们对该病的认识。
最近的发现
在千禧年之前，非甾体抗炎药（NSAIDs）是 axSpA 的唯一治疗药物，但只有 30%的患者有反应，许多患者出现了副作用。2003 年，首个生物疾病修饰药物（bDMARD）获批用于 axSpA，与 NSAIDs 相比，其显著改善了疗效。2022 年，现在有几种 bDMARD 可用于 axSpA；然而，它们在治疗轴性炎症方面并非普遍有效，并且可能对肌肉骨骼外表现有不良影响。尽管如此，每种 bDMARD 的治疗成功与否，都为 axSpA 的免疫生物学提供了宝贵的见解。本综述讨论了我们从 axSpA 中使用 bDMARD 中学到了什么，这如何重新定义了我们对该病的认识，以及我们将来如何利用这些知识为 axSpA 开发新的更好的治疗方法。
Zotero 插件